Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Technology category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals faces growing exposure as it expands the use of artificial intelligence-based solutions across its operations. Increased reliance on AI by employees and third parties heightens the risk of improper use or public disclosure of sensitive data, including trade secrets and personal information. Evolving AI-related regulations in the United States and abroad further complicate compliance obligations and increase the potential for legal or contractual liability, particularly if internal policies or data protection laws are breached. Any misuse of AI that results in data loss, biased outcomes, reputational damage, or other unintended consequences could materially and adversely impact Regeneron’s business performance, financial condition, and the market price of its common stock.
The average REGN stock price target is $857.91, implying 10.69% upside potential.
To learn more about Regeneron Pharmaceuticals’ risk factors, click here.